在炎症性皮肤疾病中通过局部IgY水凝疗法持续抑制TNFα和增强皮肤愈合
Guijie Bai1, Xiaoxuan Yin1, Yaxin Ning1
1School of Life Sciences, Faculty of Medicine, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin 300072, China.
ACS applied materials & interfaces
|July 24, 2025
概括
这项研究引入了一种创新的局部水凝系统,使用蛋黄抗体 (IgY) 来提供抗TNFα IgY,以增强伤口愈合. 在临床前模型中,IgY-Gel系统有效减少炎症并加速皮肤修复.
科学领域:
- 生物医学工程 生物医学工程
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 传统的IgG抗体对局部皮肤治疗有局限性,包括稳定性和免疫性差.
- 卵黄抗体 (IgY) 为治疗皮肤和粘膜疾病提供了卓越的热稳定性和生物安全性.
- 开发新的抗体输送系统对于有效的表皮修复至关重要.
研究的目的:
- 开发和评估一种创新的局部IgY水凝持续释放系统 (IgY-Gel),用于提供抗TNFαIgY.
- 在体外评估IgY-Gel系统的抗炎作用.
- 调查IgY-Gel系统在促进伤口愈合中的有效性.
主要方法:
- 一种含有抗TNFαIgY.Y的热敏奇托/β-甘油 (CS/β-GP) 水凝的配方.
- 使用LPS刺激的RAW264.7细胞对抗炎症活性进行体外评估,并评估内皮细胞的增殖和迁移.
- 在使用抗TNFαIgY-Gel系统的小鼠模型中体内评估伤口愈合.
主要成果:
- 反TNFαIgY-Gel系统在体外有效降低了像IL-6这样的炎症因素.
- 水凝系统在促炎条件下增强了人静脉内皮细胞 (HUVEC) 的增殖和迁移.
- 抗TNFαIgY-Gel治疗导致伤口愈合的加速,在14天后在小鼠中达到95.7%的愈合率.
结论:
- 开发的IgY-Gel系统显示了局部抗体治疗的显著抗炎和伤口愈合潜力.
- 这种创新系统克服了传统抗体的局限性,为组织修复提供了更高的疗效和安全性.
- 该IgY-Gel系统显示了工程生物学的转化应用在治疗炎症性皮肤疾病的前景.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203
Inflammatory Response
7.5K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
7.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Inflammatory Bowel Disease IV: Pharmacological Management
193
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
193
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K


